Chamomile Flower Extract

Chamomile (Matricaria chamomilla) is one of the world's most widely consumed herbal botanicals, with a tradition of use for digestive and nervous system comfort stretching back thousands of years across European, Egyptian, and Middle Eastern cultures.

GLPrelief uses a 10:1 chamomile flower extract — meaning each milligram of extract is concentrated from 10 milligrams of raw chamomile flower. This delivers a higher concentration of the flower's active compounds, including apigenin, in a compact form suitable for a stick pack format.

Chamomile serves a dual purpose in the GLPrelief formula: digestive comfort and gentle nervous system support.

For GLP-1 medication users navigating digestive adaptation, a botanical that supports both stomach comfort and a sense of calm addresses two frequently co-occurring concerns. The physician selected chamomile to complement ginger's more targeted stomach-comfort mechanism with a broader digestive-and-calming profile.

Chamomile also pairs naturally with L-Theanine in the blend — both support a calm state through different pathways, creating a complementary rather than redundant effect.

The 10:1 extract concentration means the chamomile in GLPrelief is equivalent to a significantly larger amount of raw chamomile flower — delivering the active compounds in a form that fits within the stick pack format without requiring large doses of bulky plant material.

Digestive comfort and a sense of calm. Chamomile flower extract supports digestive comfort and promotes a sense of calm.*

Chamomile is one of the most traditionally used botanicals worldwide. Its active compounds — particularly the flavonoid apigenin — have been studied for digestive and calming properties. While the clinical evidence base for chamomile is less extensive than for ginger or L-Theanine, its long history of traditional use and favorable safety profile support its inclusion as a complementary botanical in the GLPrelief blend.

GLPrelief's claims for chamomile are positioned conservatively, reflecting the traditional-use evidence base rather than specific clinical trial outcomes.

No direct studies in GLP-1 medication users have been conducted.